Cogent Biosciences rises after US FDA agrees to review rare‑disease drug

Cogent Biosciences

16/03/2026 12:42

** Shares of drug developer Cogent Biosciences  COGT.O rise 11.2% to $37.8 premarket

** Co says the U.S. Food and Drug Administration has accepted to review its experimental drug bezuclastinib for treating patients with a disease known as non‑advanced systemic mastocytosis (NonAdvSM)

** NonAdvSM is a rare condition where certain immune cells build up in the body more than they should, causing symptoms including skin flushing, stomach issues, tiredness and headaches

** COGT says it has received a target action date of December 30 for bezuclastinib

** Stock on track to break six-day losing streak if gains hold

** As of last close, COGT was down 4.3% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))